KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Payables: 2010-2025

Historic Payables for Emergent BioSolutions (EBS) over the last 15 years, with Sep 2025 value amounting to $57.4 million.

  • Emergent BioSolutions' Payables fell 30.76% to $57.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.1 million, marking a year-over-year decrease of 85.70%. This contributed to the annual value of $60.9 million for FY2024, which is 88.42% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Payables of $57.4 million as of Q3 2025, which was down 9.89% from $63.7 million recorded in Q2 2025.
  • Emergent BioSolutions' Payables' 5-year high stood at $1.1 billion during Q1 2023, with a 5-year trough of $57.4 million in Q3 2025.
  • For the 3-year period, Emergent BioSolutions' Payables averaged around $371.3 million, with its median value being $511.1 million (2024).
  • Its Payables has fluctuated over the past 5 years, first spiked by 673.87% in 2023, then slumped by 89.61% in 2025.
  • Quarterly analysis of 5 years shows Emergent BioSolutions' Payables stood at $160.5 million in 2021, then spiked by 560.93% to $1.1 billion in 2022, then slumped by 50.42% to $525.9 million in 2023, then tumbled by 88.42% to $60.9 million in 2024, then slumped by 30.76% to $57.4 million in 2025.
  • Its Payables was $57.4 million in Q3 2025, compared to $63.7 million in Q2 2025 and $58.1 million in Q1 2025.